Inflammation in Parkinson's disease.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Advances in neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  PMID 11554012
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins

  2004cited by this paper
• FcepsilonRII/CD23 is expressed in Parkinson's disease and induces, in vitro, production of nitric oxide and tumor necrosis factor-alpha in glial cells.

  1999cited by this paper
• Up-regulated production and activation of the complement system in Alzheimer's disease brain.

  1999cited by this paper
• Activated Macrophages and Microglia Induce Dopaminergic Sprouting in the Injured Striatum and Express Brain-Derived Neurotrophic Factor and Glial Cell Line-Derived Neurotrophic Factor

  1999cited by this paper
• Manganese potentiates nitric oxide production by microglia.

  1999cited by this paper
• Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine exposure

  1999cited by this paper
• Increase in level of tumor necrosis factor (TNF)-alpha in 6-hydroxydopamine-lesioned striatum in rats without influence of systemic L-DOPA on the TNF-alpha induction.

  1999cited by this paper
• MHC class II positive microglia and lymphocytic infiltration are present in the substantia nigra and striatum in mouse model of Parkinson's disease.

  1999cited by this paper
• The inflammatory reaction following 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine intoxication in mouse.

  1999cited by this paper
• Short communication Interleukin‐6 levels in cerebrospinal fluid inversely correlate to severity of Parkinson's disease

  1998cited by this paper
• Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System

  1998cited by this paper
• Transcription factor NF-kappaB: friend or foe of neurons?

  1998cited by this paper
• Induction of Interleukin-1 Associated with Compensatory Dopaminergic Sprouting in the Denervated Striatum of Young Mice: Model of Aging and Neurodegenerative Disease

  1998cited by this paper
• Effects of repeated systemic administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to mice on interleukin-1beta and nerve growth factor in the striatum.

  1998cited by this paper
• Aspirin and Salicylate Protect Against MPTP‐Induced Dopamine Depletion in Mice

  1998cited by this paper
• Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).

  1998cited by this paper
• Chromogranin A induces a neurotoxic phenotype in brain microglial cells.

  1998cited by this paper
• Activated microglia cause iron‐dependent lipid peroxidation in the presence of ferritin

  1998cited by this paper
• Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice.

  1997cited by this paper
• Regulation of glutamate in cultures of human monocytic THP-1 and astrocytoma U-373 MG cells.

  1997cited by this paper
• Nuclear translocation of NF-kappaB is increased in dopaminergic neurons of patients with parkinson disease.

  1997cited by this paper
• Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.

  1997cited by this paper
• Cyclosporin A attenuates degeneration of dopaminergic neurons induced by 6-hydroxydopamine in the mouse brain.

  1996cited by this paper
• Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease

  1996cited by this paper
• Chromogranin A triggers a phenotypic transformation and the generation of nitric oxide in brain microglial cells.

  1996cited by this paper
• Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

  1995cited by this paper
• The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases.

  1995cited by this paper
• Cytokines regulate the cellular phenotype of developing neural lineage species

  1995cited by this paper
• Glutamate production by cultured microglia: differences between rat and mouse, enhancement by lipopolysaccharide and lack effect of HIV coat protein gp120 and depolarizing agents.

  1994cited by this paper
• Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.

  1994cited by this paper
• Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients.

  1994cited by this paper
• Expression of chromogranin A in lesions in the central nervous system from patients with neurological diseases.

  1994cited by this paper
• Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients.

  1994cited by this paper
• Suppressive effect of FK-506, a novel immunosuppressant, against MPTP-induced dopamine depletion in the striatum of young C57BL/6 mice.

  1994cited by this paper
• Developmental expression of cytokine genes in the cortex and hippocampus of the rat central nervous system.

  1994cited by this paper
• Clinical trial of indomethacin in Alzheimer's disease

  1993cited by this paper
• Microglial response to 6-hydroxydopamine-induced substantia nigra lesions.

  1989cited by this paper
• Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

  1988cited by this paper

• The Lung-Brain Axis in Chronic Obstructive Pulmonary Disease-Associated Neurocognitive Dysfunction: Mechanistic Insights and Potential Therapeutic Options

  2025cites this paper
• Association between Parkinson disease and selenium levels in the body: A systematic review and meta-analysis

  2024cites this paper
• The Neuroprotective Role of BCG Vaccine in Movement Disorders: A Review.

  2022cites this paper
• Effect of Subthalamic Stimulation and Electrode Implantation in the Striatal Microenvironment in a Parkinson’s Disease Rat Model

  2022cites this paper
• "Recent challenges and trends in forensic analysis: Δ9-THC isomers pharmacology, toxicology and analysis".

  2022cites this paper
• Are Cell-Based Therapies Safe and Effective in the Treatment of Neurodegenerative Diseases? A Systematic Review with Meta-Analysis

  2022cites this paper
• Apomorphine Reduces A53T α-Synuclein-Induced Microglial Reactivity Through Activation of NRF2 Signalling Pathway

  2021cites this paper
• Increased YKL-40 but Not C-Reactive Protein Levels in Patients with Alzheimer’s Disease

  2021cites this paper
• Cannabidiol as a Therapeutic Target: Evidence of its Neuroprotective and Neuromodulatory Function in Parkinson’s Disease

  2020cites this paper
• Nonsteroidal Anti‐inflammatory Use and LRRK2 Parkinson's Disease Penetrance

  2020cites this paper
• Design, Synthesis, and Biological Evaluation of Phenol Bioisosteric Analogues of 3-Hydroxymorphinan

  2019cites this paper
• The Role of Immunosenescence in Neurodegenerative Diseases

  2018cites this paper
• Therapeutic potential of agmatine for CNS disorders

  2017cites this paper
• Immunomodulation of Parkinson's disease using Mucuna pruriens (Mp).

  2017cites this paper
• Ischemic optic neuropathy as a model of neurodegenerative disorder: A review of pathogenic mechanism of axonal degeneration and the role of neuroprotection.

  2017cites this paper
• 4R-Cembranoid Improves Outcomes after 6-Hydroxydopamine Challenge in Both In vitro and In vivo Models of Parkinson's Disease

  2017cites this paper
• Early-Life Toxic Insults and Onset of Sporadic Neurodegenerative Diseases-an Overview of Experimental Studies.

  2016cites this paper
• Overexpression of Annexin A1 Suppresses Pro-Inflammatory Factors in PC12 Cells Induced by 1-Methyl-4-Phenylpyridinium

  2016cites this paper
• Alpha-Synuclein Proteins Promote Pro-Inflammatory Cascades in Microglia: Stronger Effects of the A53T Mutant

  2016cites this paper
• Gene-environment interactions linking air pollution and inflammation in Parkinson's disease.

  2016cites this paper
• Amyloid fibrils are the molecular trigger of inflammation in Parkinson's disease.

  2015cites this paper
• Abnormal lipopolysaccharide binding protein as marker of gastrointestinal inflammation in Parkinson disease

  2015cites this paper
• Human olfactory bulb neural stem cells mitigate movement disorders in a rat model of Parkinson's disease

  2015cites this paper
• Tea Polyphenols in Parkinson's Disease.

  2015cites this paper
• Upregulation of alphaB-crystallin expression in the substantia nigra of patients with Parkinson's disease.

  2015cites this paper
• The association between chronic obstructive pulmonary disease and Parkinson's disease: a nationwide population-based retrospective cohort study.

  2014cites this paper
• Fetal programming of the human brain: is there a link with insurgence of neurodegenerative disorders in adulthood?

  2014cites this paper
• 7,8-Dihydroxyflavone attenuates the release of pro-inflammatory mediators and cytokines in lipopolysaccharide-stimulated BV2 microglial cells through the suppression of the NF-κB and MAPK signaling pathways.

  2014cites this paper
• Opposite Effects of Bone Marrow-Derived Cells Transplantation in MPTP-rat Model of Parkinson's Disease: A Comparison Study of Mononuclear and Mesenchymal Stem Cells

  2014cites this paper
• PACAP Protects Against Inflammatory-Mediated Toxicity in Dopaminergic SH-SY5Y Cells: Implication for Parkinson’s Disease

  2014cites this paper
• Phosphodiesterase as a new therapeutic target for the treatment of spinal cord injury and neurodegenerative diseases.

  2014cites this paper
• β-Ionone attenuates LPS-induced pro-inflammatory mediators such as NO, PGE2 and TNF-α in BV2 microglial cells via suppression of the NF-κB and MAPK pathway.

  2013cites this paper
• Inhibition of Src tyrosine kinase activity by squamosamide derivative FLZ attenuates neuroinflammation in both in vivo and in vitro Parkinson's disease models.

  2013cites this paper
• NADPH oxidase and aging drive microglial activation, oxidative stress, and dopaminergic neurodegeneration following systemic LPS administration

  2013cites this paper
• NRSF/REST neuronal deficient mice are more vulnerable to the neurotoxin MPTP.

  2013cites this paper
• Infections as a risk factor for Parkinson's disease: a case–control study

  2013cites this paper
• Mapping and kinetics of microglia/neuron cell‐to‐cell contacts in the 6‐OHDA murine model of Parkinson's disease

  2013cites this paper
• Glaucoma: An Extension of Various Chronic Neurodegenerative Disorders

  2013cites this paper
• Metal Dyshomeostasis and Inflammation in Alzheimer's and Parkinson's Diseases: Possible Impact of Environmental Exposures

  2013cites this paper
• Cellular and Molecular Mediators of Neuroinflammation in the Pathogenesis of Parkinson's Disease

  2013cites this paper
• Recent advances in the development of selective CB(2) agonists as promising anti-inflammatory agents.

  2012cites this paper
• Longitudinal and parallel monitoring of neuroinflammation and neurodegeneration in a 6‐hydroxydopamine rat model of Parkinson's disease

  2012cites this paper
• Whole Brain Radiation-Induced Cognitive Impairment: Pathophysiological Mechanisms and Therapeutic Targets

  2012cites this paper
• Immunopathogenesis of neurodegenerative diseases: current therapeutic models of neuroprotection with special reference to natural products.

  2012cites this paper
• A comprehensive study on long‐term injury to nigral dopaminergic neurons following intracerebroventricular injection of lipopolysaccharide in rats

  2012cites this paper
• Aging-Associated Alteration of Telomere Length and Subtelomeric Status in Female Patients With Parkinson's Disease

  2012cites this paper
• Regulation of oxidative stress in long‐lived lipopolysaccharide‐activated microglia

  2012cites this paper
• Current Understanding of the Glial Response to Disorders of the Aging CNS

  2012cites this paper
• Anti-parkinsonian effects of Nurr1 activator in ubiquitin-proteasome system impairment induced animal model of Parkinson's disease.

  2012cites this paper
• The immunological challenges of cell transplantation for the treatment of Parkinson's disease.

  2012cites this paper
• Pathways towards an effective immunotherapy for Parkinson’s disease

  2011cites this paper
• Neuroprotective and anti‐inflammatory effects of the adenosine A2A receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease

  2011cites this paper
• Epidemiology and etiology of Parkinson’s disease: a review of the evidence

  2011cites this paper
• Neuroprotection of desferrioxamine in lipopolysaccharide-induced nigrostriatal dopamine neuron degeneration.

  2011cites this paper
• Role of microglia in CNS inflammation

  2011cites this paper
• Potential of cystamine and cysteamine in the treatment of neurodegenerative diseases.

  2011cites this paper
• What has gene expression profiling taught us about glaucoma?

  2011cites this paper
• Structure-Dependent Inhibition of Gelatinases by Dietary Antioxidants in Rat Astrocytes and Sera of Multiple Sclerosis Patients

  2011cites this paper
• Trimethyltin-induced hippocampal degeneration as a tool to investigate neurodegenerative processes.

  2011cites this paper
• BCG Vaccine-Induced Neuroprotection in a Mouse Model of Parkinson's Disease

  2011cites this paper
• c-Abl in Neurodegenerative Disease

  2011cites this paper
• Past, present and future of A(2A) adenosine receptor antagonists in the therapy of Parkinson's disease.

  2011cites this paper
• Glial cell line-derived neurotrophic factor protects midbrain dopaminergic neurons against lipopolysaccharide neurotoxicity

  2010cites this paper
• Acupuncture-mediated inhibition of inflammation facilitates significant functional recovery after spinal cord injury.

  2010cites this paper
• Reimagining Alzheimer's Disease—An Age-Based Hypothesis

  2010cites this paper
• Neuroinflammation is a key player in Parkinson’s disease and a prime target for therapy

  2010cites this paper
• Targeting Glial Cells to Elucidate the Pathogenesis of Huntington’s Disease

  2010cites this paper
• Cilostazol is anti‐inflammatory in BV2 microglial cells by inactivating nuclear factor‐kappaB and inhibiting mitogen‐activated protein kinases

  2010cites this paper
• Trichloroethylene induces dopaminergic neurodegeneration in Fisher 344 rats

  2010cites this paper
• Neuroinflammation and the prospects for anti-inflammatory treatment of Parkinson's disease.

  2010cites this paper
• Anti-inflammatory effects of cordycepin via suppression of inflammatory mediators in BV2 microglial cells.

  2010cites this paper
• Association between sporadic Parkinson disease and interleukin-1 beta -511 gene polymorphisms in the Turkish population.

  2010cites this paper
• Elevated interleukin-1beta induced by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine aggravating dopaminergic neurodegeneration in old male mice.

  2009cites this paper
• Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival.

  2009cites this paper
• Effects of IL-6 secreted from astrocytes on the survival of dopaminergic neurons in lipopolysaccharide-induced inflammation.

  2009cites this paper
• Nutrition, Inflammation, and Cognitive Function

  2009cites this paper
• Nur(R1)turing a Notion on the Etiopathogenesis of Parkinson’s Disease

  2009cites this paper
• Recent advances in our understanding of neurodegeneration

  2009cites this paper
• Neuroprotective Effect of Ghrelin in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model of Parkinson’s Disease by Blocking Microglial Activation

  2009cites this paper
• Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation.

  2009cites this paper
• Parkinson's disease and inflammatory changes

  2009cites this paper
• Neuroprotective effect of Scutellaria baicalensis on spinal cord injury in rats

  2009cites this paper
• Intrastriatal lipopolysaccharide injection induces parkinsonism in C57/B6 mice

  2009cites this paper
• Autoimmune pathology accounts for common manifestations in a wide range of neuro-psychiatric disorders: the olfactory and immune system interrelationship.

  2009cites this paper
• Aging-associated alteration of subtelomeric methylation in Parkinson's disease.

  2009cites this paper
• Microglia of rat ventral midbrain recovers its resting state over time in vitro: Let microglia rest before work

  2009cites this paper
• Frataxin deficiency induces Schwann cell inflammation and death.

  2009cites this paper
• Protective properties afforded by pioglitazone against intrastriatal LPS in Sprague-Dawley rats.

  2008cites this paper
• Anti-inflammatory effects of catechols in lipopolysaccharide-stimulated microglia cells: inhibition of microglial neurotoxicity.

  2008cites this paper
• Predominant release of lysosomal enzymes by newborn rat microglia after LPS treatment revealed by proteomic studies.

  2008cites this paper
• Curcumin Protects Dopaminergic Neuron Against LPS Induced Neurotoxicity in Primary Rat Neuron/Glia Culture

  2008cites this paper
• Nitrated Alpha-Synuclein and Microglial Neuroregulatory Activities

  2008cites this paper
• Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson's disease

  2008cites this paper
• Mitochondrial Dysfunction and Oxidative Stress in Parkinson’s Disease

  2008cites this paper
• Protective effects of genistein on proinflammatory pathways in human brain microvascular endothelial cells.

  2008cites this paper
• Synthesis of azaisoflavones and their inhibitory activities of NO production in activated microglia.

  2008cites this paper
• AMPHETAMINE-INDUCED DOPAMINERGIC TOXICITY: A SINGLE DOSE ANIMAL MODEL OF PARKINSON'S DISEASE

  2008cites this paper
• Cannabinoid CB2 receptors in human brain inflammation

  2008cites this paper
• A percentage analysis of the telomere length in Parkinson's disease patients.

  2008cites this paper
• Neurological Benefits of Omega-3 Fatty Acids

  2008cites this paper